Participated · Series A · Feb 2021

Coya Therapeutics is a clinical-stage biotech focused on enhancing regulatory T cell (Treg) function through multiple platforms, including expanded autologous “Super Tregs,” Treg-derived exosome therapeutics, and a novel biologic to upregulate Tregs in vivo. Clinical and biomarker data reported by the company indicate Tregs can meaningfully dampen systemic and neuroinflammation, and preclinical data show positive effects of Treg-derived exosomes in neuro and systemic inflammation. Key programs include COYA 101 (scalable expanded autologous Treg therapy for ALS), COYA 201 (autologous Treg-derived exosome for ALS), and COYA 202 (allogeneic Treg-derived exosome for FTD), with plans to advance multiple programs into Phase 1 and a well-powered Phase 2b. Coya is also preparing an IND-directed biologic program for ALS, FTD, and Alzheimer’s disease and is advancing allogeneic exosome programs for autoimmune and metabolic disorders. The company emphasizes building clinical, scientific, and manufacturing capabilities and plans to report multiple preclinical and clinical data readouts over the next several quarters. Coya is headquartered in Houston, Texas. Coya Therapeutics is a clinical-stage biotech developing first-in-class approaches using autologous regulatory T cells (Tregs) and allogeneic exosome therapeutics to address neurodegenerative and autoimmune diseases. The company leverages seminal discoveries from Dr. Stanley H. Appel and its patented TAI™ (Tregs Against Inflammation) and EAITM (Exosomes Against Inflammation) platforms. Its proprietary CTreg™ cryopreservation system enables expansion, freezing, and re-thawing of Tregs while maintaining viability and suppressive function to support an off-the-shelf, serial-infusion model. Coya’s lead program, ALS001, is an autologous, expanded Treg therapy for ALS and the company reports phase 1 data demonstrating safety and tolerability of expanded Treg infusions. Planned pipeline advancement includes clinical candidates targeting Parkinson’s, Alzheimer’s, frontotemporal dementia and other autoimmune diseases, plus non-cell based exosomes, combined therapies, and small-molecule candidates. The company intends to use proceeds to advance programs into the clinic and to optimize and scale manufacturing and CMC readiness.